Cardiovascular Biology of Interleukin-6
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine that is tightly regulated and expressed at low levels in healthy individuals. Increased IL-6 expression has been associated with a variety of diseases, including inflammatory conditions such as atherosclerosis and cardiovascular disease (obesity, myocardial infarction and type II diabetes). Cytokines including IL-6 and tumour necrosis factor alpha as well as acute phase proteins such as C-reactive protein (CRP) and fibrinogen are key biochemical risk factors for the development of these disease conditions. IL-6 is the key cytokine responsible for the stimulus of synthesis and secretion of CRP. IL-6 activates cell surface signalling via the assembly of IL-6, the IL-6 receptor (IL-6R) and the signalling receptor gp130. Assembly of the (hexameric) signalling complex of IL-6, IL-6R and gp130 occurs in a sequential manner and therefore this signalling complex lends itself to several potential sites for drug targeting. This review discusses some of the mechanisms of IL-6 signalling on various aspects of cardiovascular biology as well as some recent developments in drug targeting of this complex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 3×
“Abbreviations: Janus kinase (JAK), signal transducer and activator of transcription (STAT), suppressor of cytokine signalling (SOCS), tyrosine kinase (Tyrk). rearrangement of the receptor with a phosphorylation of the associated JAKs.”
BackgroundYudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 3×
“Abbreviations: Janus kinase (JAK), signal transducer and activator of transcription (STAT), suppressor of cytokine signalling (SOCS), tyrosine kinase (Tyrk). rearrangement of the receptor with a phosphorylation of the associated JAKs.”
BackgroundInflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?
Yudkin, J. S., Kumari, M., Humphries, S. E., & Mohamed-Ali, V. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00463-3 · Cited by 1,775
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692 · cited 1×
“It is now believed that chronic low grade inflammation may play a role in the development of cardiovascular disease as well as insulin resistance, diabetes and obesity [6, 7].”
BackgroundInflammation as a Cardiovascular Risk Factor
Willerson, J. T., & Ridker, P. M. (2004) · Circulation · doi:10.1161/01.cir.0000129535.04194.38 · Cited by 1,304 · cited 1×
“Cellular adhesion molecules regulate the adhesion of white blood cells to the vessel wall whilst tissue factors promote coagulation [55].”
BackgroundInterleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213 · cited 1×
“IL-6 knockout mice developed matureonset obesity, at 6 months of age which was partially reversed with IL-6 replacement [129] although this is controversial, as Di Gregorio and colleagues found that there was no difference in the body composition between IL-6 deficient and wild-type mice [130].”
BackgroundCarey, A. L., Steinberg, G. R., Macaulay, S. L., Thomas, W. G., Holmes, A. G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M. J., James, D. E., et al. (2006) · Diabetes · doi:10.2337/db05-1404 · Cited by 898 · cited 1×
“These cellular metabolic effects of IL-6 are thought to be mediated via the activation of AMP-activated protein kinase (AMPK) since the metabolic effects of IL-6 were absent in myotubes infected with dominant negative AMPK -subunit [43, 125].”
BackgroundInterleukin-6 induces cellular insulin resistance in hepatocytes.
Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3391 · Cited by 883 · cited 1×
“This is supported by in vitro data which demonstrated that exposure to IL-6 inhibits insulin receptor signal transduction and insulin action in hepatocytes [128].”
ResultMcKeown, N. M., Meigs, J. B., Liu, S., Saltzman, E., Wilson, P. W. F., & Jacques, P. F. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.538 · Cited by 786 · cited 1×
“Cardiovascular disease is closely linked with risk factors such as elevated total cholesterol, insulin resistance, diabetes and obesity, and these risk factors are also increasing in developing countries [2-4].”
BackgroundInterleukin-6 stimulates lipolysis and fat oxidation in humans
van Hall, G., Steensberg, A., Sacchetti, M., Fischer, C., Keller, C., Schjerling, P., Hiscock, N., Møller, K., Saltin, B., Febbraio, M. A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021687 · Cited by 767 · cited 1×
“In addition, infusion of IL-6 increases plasma fatty acid concentrations, fat oxidation [123] and the expression of IL-6 mRNA in skeletal muscle [119] while also increasing hormones such as cortisol and adrenaline [123, 124].”
BackgroundDanesh, J., Kaptoge, S., Mann, A. G., Sarwar, N., Wood, A., Angleman, S. B., Wensley, F., Higgins, J. P. T., Lennon, L., Eiriksdottir, G., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050078 · Cited by 676 · cited 1×
“A recent study which evaluated associations of long term circulating IL-6 levels with CHD risk in two population based cohort studies along with a systematic review has suggested a strong association akin to those described for major established risk factors whilst the exact causality remain unresolved [51].”
BackgroundFernandez-Real, J.-M., Vayreda, M., Richart, C., Gutierrez, C., Broch, M., Vendrell, J., & Ricart, W. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7305 · Cited by 567 · cited 2×
“IL-6 concentration correlates with arterial blood pressure in healthy adults [62, 63] and is increased in patients suffering from cardiovascular disease and atherosclerosis [64].”
BackgroundDifferential Effects of Interleukin-6 and -10 on Skeletal Muscle and Liver Insulin Action In Vivo
Kim, H.-J., Higashimori, T., Park, S.-Y., Choi, H., Dong, J., Kim, Y.-J., Noh, H.-L., Cho, Y.-R., Cline, G., Kim, Y.-B., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1060 · Cited by 534
IL-6 and TNF-α expression in, and release from, contracting human skeletal muscle
Steensberg, A., Keller, C., Starkie, R. L., Osada, T., Febbraio, M. A., & Pedersen, B. K. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00255.2002 · Cited by 410 · cited 1×
“Plasma IL-6 concentrations are increased with increasing exercise [118], which are a result of an increased expression of IL-6 mRNA in both skeletal muscle [119, 120] and adipose tissue [121, 122].”
BackgroundHan, Y., Runge, M. S., & Brasier, A. R. (1999) · Circulation Research · doi:10.1161/01.res.84.6.695 · Cited by 377
Cytokine and cytokine receptor gene polymorphisms and their functionality
Smith, A. J. P., & Humphries, S. E. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.006 · Cited by 374 · cited 1×
“The IL-6 gene does not contain any common polymorphisms within coding regions and therefore attention has focused on promoter polymorphisms [24] and in particular, the common IL-6 -174 G>C polymorphism [25, 26].”
BackgroundReddy, K. S. (2002) · Public Health Nutrition · doi:10.1079/phn2001298 · Cited by 314
Albert, M. A., Glynn, R. J., Buring, J., & Ridker, P. M. (2006) · Circulation · doi:10.1161/circulationaha.106.660043 · Cited by 262
Inhibition of IL-6 for the treatment of inflammatory diseases
NISHIMOTO, N. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.005 · Cited by 200
Steensberg, A., Fischer, C. P., Sacchetti, M., Keller, C., Osada, T., Schjerling, P., van Hall, G., Febbraio, M. A., & Pedersen, B. K. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.032938 · Cited by 152
Ryan, K. E., McCance, D. R., Powell, L., McMahon, R., & Trimble, E. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.007 · Cited by 94 · cited 1×
“[131] showed that PPAR and PPAR agonist (fenofibrate and pioglitazone, respectively) treatment of obese, glucose tolerant men, reduced several pro-inflammatory cytokines, including IL-6.”
Background
Cited by
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
Obesity, Inflammation, and Cardiovascular Risk
Mathieu, P., Lemieux, I., & Després, J.-P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.311 · Cited by 419
You, T., Arsenis, N. C., Disanzo, B. L., & LaMonte, M. J. (2013) · Sports Medicine · doi:10.1007/s40279-013-0023-3 · Cited by 285
Yao, Y., Bennett, B. J., Wang, X., Rosenfeld, M. E., Giachelli, C., Lusis, A. J., & Boström, K. I. (2010) · Circulation Research · doi:10.1161/circresaha.110.219071 · Cited by 253
Maes, M., Ruckoanich, P., Chang, Y. S., Mahanonda, N., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.008 · Cited by 169
“Nevertheless, IL-6 may contribute to atherosclerosis via atherosclerotic plaque formation and plaque destabilisation (Schuett et al., 2009; Abeywardena et al., 2009).”
Background
Metadata
- Authors
- Abeywardena, M., Leifert, W., Warnes, K., Varghese, J., & Head, R.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-05-01
- Volume
- 15
- Issue
- 15
- Pages
- 1809-1821
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2104716891
- Cited by
- 127
- References
- 22
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.